Increase in lobular breast cancer incidence in Switzerland

Levi, Fabio; Te, Van‐Cong; Randimbison, Lalao; Vecchia, Carlo La

doi:10.1002/ijc.11309

Cited by 16 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al [24] reported a plateau in the incidence of ductal breast cancer, but an increase in the incidence of lobular breast cancer between 1987 and 1995 in the US. Two studies from Switzerland [23,48] did not report a plateau, but an increased incidence rate in ductal (0.9-1.2% per year) as well as lobular (10-14% per year) breast cancer. The increase, however, was more substantial in lobular breast cancer.…”

Section: Discussionmentioning

confidence: 97%

Impact of hormone replacement therapy on the histologic subtype of breast cancer

Zanetti-Dällenbach

Krause

Lapaire

et al. 2008

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Impact of hormone replacement therapy on the histologic subtype of breast cancer

Zanetti-Dällenbach

Krause

Lapaire

et al. 2008

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

“…Data for the present report were abstracted from the Vaud Cancer Registry file, which includes incident cases of malignant neoplasms in the canton 5,21 whose population, according to the year 2000 census, was about 641,000 inhabitants. A registration scheme applying the same standardized rules as for incident malignancies, has been implemented for CIS of the breast.…”

Section: Methodsmentioning

confidence: 99%

“…[1][2][3] In recent years, CIS accounted for over 20% of breast cancers diagnosed in the United States (i.e., over 50,000 cases per year) 1,4 and Europe. 5,6 Substantial upward trends were observed earlier for ductal CIS (DCIS) 7 and, more recently, for lobular CIS (LCIS). 5,6 The prognosis of women diagnosed with breast CIS is also poorly defined.…”

mentioning

confidence: 91%

“…5,6 Substantial upward trends were observed earlier for ductal CIS (DCIS) 7 and, more recently, for lobular CIS (LCIS). 5,6 The prognosis of women diagnosed with breast CIS is also poorly defined. 2 In large clinical trials from the United States 8-11 and Europe, 12-15 the risk of ipsilateral invasive breast cancer varied between 14 and 32% according to length of follow-up and type of therapy, and that of contralateral breast cancer varied between 2 and 6.6%.Scanty population-based data are available.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Invasive breast cancer following ductal and lobular carcinomain situ of the breast

Levi

Randimbison²,

Te³

et al. 2005

Int. J. Cancer

Self Cite

View full text Add to dashboard Cite

We considered the risk of subsequent invasive breast cancer in a population-based series of 579 carcinomas in situ (CIS) of the breast (482 ductal, 88 lobular) registered between 1977 and 2002 in the Swiss Canton of Vaud. A total of 55 cases of invasive breast cancer were observed vs. 12.3 expected, corresponding to a standardized incidence ratio (SIR) of 4.5 (95% confidence interval [CI], 3.4-5.8). The SIR was 4.6 after ductal and 4.2 after lobular CIS, was similar with passing time since CIS diagnosis, but was higher (SIR = 5.5) for women aged <55 years. At 20 years following CIS, the cumulative risk of invasive breast cancer was 26%, similar for lobular and for ductal CIS. The incidence of invasive breast cancer following CIS showed no consistent pattern of trends with age, all rates in subsequent age groups ranging between 10 and 18 in 1,000. This is compatible with the occurrence of a single mutational event in a population of susceptible women. ' 2005 Wiley-Liss, Inc.Key words: breast neoplasms; cancer registry; ductal carcinoma in situ; lobular carcinoma in situ; noninvasive breast neoplasms; second primary Carcinoma in situ (CIS) of the breast is a preinvasive breast tumor that has become increasingly commonly detected in women undergoing (screening) mammography. [1][2][3] In recent years, CIS accounted for over 20% of breast cancers diagnosed in the United States (i.e., over 50,000 cases per year) 1,4 and Europe. 5,6 Substantial upward trends were observed earlier for ductal CIS (DCIS) 7 and, more recently, for lobular CIS (LCIS). 5,6The prognosis of women diagnosed with breast CIS is also poorly defined.2 In large clinical trials from the United States [8][9][10][11] and Europe, 12-15 the risk of ipsilateral invasive breast cancer varied between 14 and 32% according to length of follow-up and type of therapy, and that of contralateral breast cancer varied between 2 and 6.6%.Scanty population-based data are available. Among them, in a series of 28 noncomedo DCIS from the United States, 16 the risk of invasive breast cancer was elevated up to 30 years after diagnosis. Among 1,929 women with DCIS and 282 with LCIS from western Washington state, the risk of contralateral invasive disease was about 2-fold after DCIS and 3-fold after LCIS. 17 In the U.S. Surveillance, Epidemiology and End Results (SEER) Program, 1,525 DCIS in women 40 and older were diagnosed between 1978 and 1983 (before screening mammography was common), and 5,547 between 1984 and 1989 (when screening mammography became common). No information on incidence of subsequent invasive breast cancer was available, but the relative risks (RR) of breast cancer death were 3.4 in the first period and 1.9 in the second one.18 Another series of 3,455 CIS cases from Sweden, including 116 cases of invasive cancer, gave an RR of 4.5 for DCIS and of 4.0 for LCIS. 15 A series of 4,198 women diagnosed with CIS between 1975 and 1998 in the Connecticut Tumor Registry showed a 10-year cumulative probability of contralateral breast cancer (invasive and CIS) of ...

show abstract

“…Using data from the national Breast Cancer Surveillance Consortium (BCSC), we explored how associations with family history, parity, age at first birth, menopausal hormone therapy (HT) use, BMI, and breast density differed with histology. Since the vast majority of invasive breast cancers can be classified as having either a ductal histology (65–80%), a lobular histology (6–12%), or a mix of ductal and lobular histologic features (3–6%) (9, 11, 20, 24, 25), we focus here on these three subtypes.…”

Section: Introductionmentioning

confidence: 99%

Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population

Phipps

Kerlikowske

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Biological distinctions between histologic subtypes of breast cancer suggest etiologic differences, although few studies have been powered to examine such differences. We compared associations between several factors and risk of ductal, lobular, and mixed ductal-lobular breast cancers.Methods: We used risk factor data from the Breast Cancer Surveillance Consortium for 3,331,744 mammograms on 1,211,238 women, including 19,119 women diagnosed with invasive breast cancer following mammography (n = 14,818 ductal, 1,602 lobular, and 1,601 mixed ductal-lobular). Histologic subtype-specific risk factor associations were evaluated using Cox regression.Results: Significant positive associations with family history and breast density were similar across subtypes. Hormone therapy use was associated with increased risk of all subtypes, but was most strongly associated with lobular cancer [hazard ratio (HR) = 1.46; 95% confidence interval (CI), 1.25-1.70]. Relative to nulliparous women, parous women had lower risk of ductal and mixed but not lobular cancers (HR = 0.80; 95% CI, 0.76-0.84; HR = 0.79; 95% CI, 0.68-0.93; HR = 0.96; 95% CI, 0.81-1.15, respectively). Late age at first birth was associated with increased risk of all subtypes.Conclusions: Similarities in risk factor associations with ductal, lobular, and mixed breast cancer subtypes were more pronounced than differences. Distinctions between subtype-specific associations were limited to analyses of hormone therapy use and reproductive history.Impact: The results of this study indicate that the strongest risk factors for breast cancer overall (that is, family history and breast density) are not histologic subtype specific. Additional studies are needed to better characterize subtype-specific associations with genetic, hormonal, and nonhormonal factors. Cancer Epidemiol

show abstract

Increase in lobular breast cancer incidence in Switzerland

Cited by 16 publications

References 10 publications

Impact of hormone replacement therapy on the histologic subtype of breast cancer

Impact of hormone replacement therapy on the histologic subtype of breast cancer

Invasive breast cancer following ductal and lobular carcinomain situ of the breast

Risk Factors for Ductal, Lobular, and Mixed Ductal-Lobular Breast Cancer in a Screening Population

Contact Info

Product

Resources

About